Miguel Ángel Lorente, CEO, Transmural Biotech
The COVID-19 pandemic has exposed a gloomy state of medical science and research policy, one that undermines the existing paradigm on capabilities of progress, control, and foresight. As in the naked king’s story, everyone saw that even after the verbiage on the potential new medicine, there were basic, strategic, and tactical deficiencies that have disappointed the population. In this perplexing situation, one aspect stands out, without which it is impossible to manage either the general crises or the most serious illnesses of each person: rapid, anticipatory, comfortable, and reliable diagnostic tests.
Meet Transmural Biotech.
The company is building AI algorithms capable of diagnosing—through images and devices as common as ultrasound scanners—a wide range of very dangerous diseases. Through these images, embracing the notion of non-invasive tests, Transmural Biotech builds algorithms with excellent predictive capacity that are capable of advancing diagnosis with an immediate response.
After nine years of activity, Transmural Biotech has already demonstrated that its business is in the products that allow tests to be performed quickly, comfortably, more reliably, and faster. “We started with maternal-fetal tests (prematurity and fetal lung maturity), and now we are able, in collaboration with the medical institutions that provide us with images, to create algorithms for a very wide range of diseases in all types of ages,” mentions Miguel Ángel Lorente, the CEO of Transmural Biotech. The company already has two predictive algorithms that are marketed in 70 countries and will add five more by the end of 2020.
Yalu Liu, International Director, Transmural Biotech
In China alone, where a listed pharmaceutical group has acquired the company’s maternal-fetal products’ distribution license, more than five million of these tests will be carried out in 2021.
Regarding breast cancer, Transmural Biotech’s algorithm detects—at its current stage of our development, —23 percent more cases than what a pathologist can warn with conventional methods. Further, the company’s products can also be used to detect melanoma and dermatological diseases, where the tests can help exceed the productivity of specialists by 57 percent.
Lorente mentions that the small number of competitors in the market for making predictive algorithms based on the application of AI to medical images is astonishing. “Although there is an increasing proliferation of AI to study health data, the genetic material of pathogens, and to personalize medical treatments, the images frontier has not been tapped much by the technology,” he adds. To this end, Transmural Biotech is looking for startups to join the small group of consolidated companies like them. “We believe that the biggest movement will be when the large international pharmaceutical laboratories and industries are going to get decidedly involved (through alliances, purchases, or own developments) in AI applied to images,” says Lorente.
For the future, Transmural Biotech is working to diagnose many more complicated illnesses, as Lorente informs, “I work to find alliances that provide us with quality images that are medically well informed. We are looking forward to finding marketing agreements in geographic areas and working with manufacturers of medical imaging equipment. I work to be profitable to our shareholders and offer creative and satisfying employment for our collaborators. This year will establish us as one of the best global company that develops AI-based algorithms that diagnoses conditions from medical images.”